DOW JONES28,992.41-227.57 -0.78%
S&P 5003,337.75-35.48 -1.05%
NASDAQ9,576.59-174.38 -1.79%

Aprea Therapeutics Reports FDA Breakthrough Therapy Designation For APR-246 In Combo With Azacitidine For Treatment Of MDS With TP53 Mutation

Benzinga · 01/30/2020 12:36